series-a
Stage
1
Investors
About
Thrombolex develops FDA-cleared endovascular catheters that use a hybrid pharmacomechanical approach to treat arterial and venous thromboembolic conditions by fragmenting clots and delivering targeted thrombolytics to restore blood flow.
Explore Thrombolex's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.